Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 14/20 | 0.58 |
| ▸ | BRD1 | O95696 | 1/20 | 0.46 |
| ▸ | TAF1 | P21675 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28653674 | 0.80 | TYMS (0.53) | TYMS | |
| SCHEMBL28513208 | 0.77 | TYMS (0.50) | TYMS | |
| 1,8-Naphthalic Anhydride SCHEMBL30415 | 0.75 | TYMS (1.00) | TYMS | |
| 1,8-Naphthalic Anhydride SCHEMBL29351054 | 0.75 | TYMS (1.00) | TYMS | |
| SCHEMBL4957627 | 0.75 | TYMS (0.67) | TYMS | |
| SCHEMBL9079545 | 0.75 | CA1 (0.46) | TYMSCA1CA2 | |
| SCHEMBL21650723 | 0.75 | TYMS (0.47) | TYMS | |
| SCHEMBL4960941 | 0.74 | TYMS (0.64) | TYMS | |
| SCHEMBL22580797 | 0.74 | TYMS (0.64) | TYMS | |
| SCHEMBL1565203 | 0.74 | TYMS (0.64) | TYMSBRD1TAF1BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| WO-2009039635-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-04-02 | — | — | WO | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| EP-1931637-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2008-06-18 | — | — | EP | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | TYMS 3892/4885BRD1 4211/4885TAF1 4741/4885 |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | TYMS 3892/4885BRD1 4211/4885TAF1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.